R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study，lenalidomide was added in the first-line treatment in the newly diagnosed highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared with the classical R-CHOP/R-EPOCH etc. The investigators tried to explore a more effective and safe treatment regimen for patients with high-risk B-cell lymphoma to improve the patient's poor prognosis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shandong Provincial Hospital
• Treatments: Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Etoposide phosphate; Lenalidomide; Liposomal doxorubicin; Prednisone; Rituximab; Vincristine; Vindesine

Criteria

Inclusion Criteria:

1. Newly diagnosed highly aggressively B-Cell Non-Hodgkin's lymphoma (NHL) confirmed by histopathology

2. The patient has at least ≥1 measurable tumor lesion with a diameter >1.5 cm;

3. The patient has not undergone systemic chemotherapy or immunotherapy before;

4. ECOG score ≤ 2 points;

5. Liver and kidney function meets the following conditions: creatinine clearance rate ≥ 30ml / min, total bilirubin, AST and ALT ≤ 2.5 × ULN;

6. No history of malignant tumors within 5 years, except for cured carcinomas in situ such as basal cell carcinoma of the skin, cervical cancer, breast cancer, prostate cancer, etc.;

7. agree to take contraceptive measures during the trial period and within 3 months after the end of the trial;

8. Patients volunteered to participate in the study and signed informed consent.

Exclusion Criteria:

1. Serious cardiovascular and other important organs and blood, endocrine system lesions, and other history of malignant tumors;

2. Severe mental illness;

3. Pregnant or lactating women and men or women who intend to conceive in the near future;

4. The expected survival time is less than 6 months;

5. HBV, HCV or HIV infection or seropositive;

6. there are active infections;

7. Allergies or allergies to rituximab;

8. Compliance or poor follow-up;

9. Other circumstances that the investigator believes are not suitable for inclusion.